Lessons along the Critical Path: Developing Vaccines against Human Helminths

Area of Science:

• Parasitology
• Vaccinology
• Global Health

Background:

• Helminthic parasites affect approximately 1 billion people globally, necessitating effective vaccine solutions.
• Despite advances in antigen discovery, developing helminth vaccines for human trials faces significant hurdles.
• The path to vaccine approval involves preclinical research, manufacturing, and clinical testing.

Purpose of the Study:

• To describe critical lessons learned in advancing helminth vaccine candidates.
• To highlight challenges in the vaccine development pathway for neglected tropical diseases.
• To share insights from a product development partnership focused on helminth vaccines.

Main Methods:

• Review of the vaccine development process for novel subunit vaccines.
• Focus on the critical path from preclinical research to regulatory approval.
• Experience gained from developing vaccines for Necator americanus and Schistosoma mansoni.

Main Results:

• The vaccine development pathway requires meticulous attention to chemistry, manufacturing, and controls (CMC).
• Achieving safety, immunogenicity, and efficacy criteria set by regulatory bodies like the FDA is paramount.
• Product development partnerships (PDP) play a crucial role in navigating this complex process.

Conclusions:

• Advancing helminth vaccines requires overcoming substantial preclinical and manufacturing challenges.
• Successful vaccine development necessitates adherence to current good manufacturing practice (cGMP) and regulatory standards.
• Lessons learned from the Texas Children's Hospital Center for Vaccine Development (TCH-CVD) offer valuable insights for future helminth vaccine research.